Thermo Fisher Scientific has enrolled the first patient in a prospective observational registry designed to generate real-world evidence on obesity treatments. The regirstry includes anti-obesity medications and GLP-1 receptor agonists. The PPD CorEvitas Obesity Registry will collect longitudinal data from both clinicians and patients. It will track how therapies are used in practice, how long…
Novo slashes US GLP-1 prices by up to 70%, but 2026 semaglutide revenue could hold steady or even grow
Novo Nordisk, which helped kickstart the GLP-1 craze by expanding a diabetes drug to obesity, is slimming down the prices of Ozempic and Wegovy. That won’t necessarily translate into steep revenue drops in 2026 though. Current projections still point to rising semaglutide sales next year, and a drop in price could lead to a boost…
Trump’s $150 Ozempic vow hits Novo, Lilly, even as Oz says ‘we have not negotiated those yet’
It took just one off-hand comment during a White House event about fertility treatments for President Trump to temporarily wipe tens of billions from the market cap of the world’s leading obesity drugmakers. Trump’s vow Thursday to bring Ozempic down to $150 per month, calling it “the fat-loss drug,” sent Novo Nordisk shares down 6.3%…
Lilly shakes up obesity drug market with Zepbound self-pay price now up to 70% lower than the competition
GLP-1 therapies just got a whole lot less expensive for patients who pay out of pocket. Eli Lilly’s Zepbound (tirzepatide) single-dose vials are now available at rates similar to compounded versions of semaglutide. Patients can now access a four-week supply of Zepbound for as little as $399 for the 2.5 mg dose and $549 for…
Can payers afford the new era of GLP-1 drugs? Or can they afford not to?
The latest crop of glucagon-like peptide-1 (GLP-1) agonists, such as semaglutide and tirzepatide (technically, a dual GIP/GLP-1 receptor agonist), have upended the way we treat metabolic disorders, including obesity. These drugs mimic gut hormones, improving blood sugar control and often leading to significant weight loss. But as Kyasha Sri Ranjan, Ph.D., engagement manager at Lifescience…
High-profile drugs under the legal spotlight in 2023
In the wake of the COVID-19 pandemic, the U.S. has witnessed a surge in litigation. One factor driving the uptick in the pharmaceutical sector is the rise of copycat litigation. As mass tort activity amplifies, plaintiff lawyers are treating previously filed lawsuits as templates for new claims. Examples of the trend include steadily increasing nitrosamines…